February 22, 2021
Astellas Pharma said on February 19 that its oral non-hormonal agent fezolinetant achieved the primary endpoints in two global PII studies for the treatment of moderate-to-severe menopausal vasomotor symptoms (VMS), known as hot flashes. The positive topline results were reported...read more